Form 4: BVF Partners Reduces Stake in XOMA Royalty Corp Through Multiple Transactions

BVF Partners L.P. and related entities have sold a significant number of XOMA Royalty Corp common shares, while maintaining a substantial position through direct and indirect holdings.

Summary

• BVF Partners L.P. and its related entities, collectively referred to as the Reporting Persons, have filed a Form 4 detailing changes in their beneficial ownership of XOMA Royalty Corp stock.
• On January 24, 2025, the Reporting Persons sold a total of 650,717 shares of XOMA common stock at a price of $26.1 per share.
• These transactions reduced their direct holdings of common stock, but they continue to hold a significant number of shares both directly and indirectly.
• The Reporting Persons also hold Series X Convertible Preferred Stock, which can be converted into common stock, subject to a 19.99% ownership limit.
• The Reporting Persons include Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and several related entities, all of which are part of a Section 13(d) group owning more than 10% of XOMA's outstanding shares.

Sentiment

Score: 4

Explanation: The document indicates a reduction in a major shareholder's position, which is generally viewed negatively by the market. However, the continued holding of a significant stake and convertible preferred stock mitigates some of the negative sentiment.

Negatives

• The sale of 650,717 shares by BVF Partners and related entities could be viewed negatively by the market, potentially indicating a reduced confidence in XOMA's near-term prospects.

Risks

• The potential conversion of Series X Convertible Preferred Stock could significantly increase the number of outstanding common shares, potentially diluting the value of existing shares.
• The 19.99% ownership limit on the conversion of preferred stock could create uncertainty about the future ownership structure of XOMA.

Future Outlook

The document does not contain any specific forward-looking statements or guidance from the company. However, the potential conversion of preferred stock could significantly impact the future share structure.

Industry Context

Form 4 filings are a standard part of regulatory compliance for significant shareholders and provide transparency into their trading activities. This filing indicates a change in BVF Partners' investment position in XOMA, which could be of interest to other investors in the biotechnology royalty space.

Comparison to Industry Standards

• Form 4 filings are a standard practice for reporting changes in beneficial ownership by insiders and large shareholders in publicly traded companies, such as XOMA.
• The transactions are similar to those seen in other biotech companies where large institutional investors adjust their positions based on market conditions and company performance.
• The sale of shares by BVF Partners is not unusual, as institutional investors regularly rebalance their portfolios. However, the size of the sale may be significant for XOMA.

Stakeholder Impact

• The sale of shares by BVF Partners may negatively impact shareholder confidence and potentially the share price.
• The potential conversion of preferred stock could dilute existing shareholders' equity.

Key Dates

Keywords

XOMA Royalty Corp, BVF Partners, stock sale, beneficial ownership, Form 4, convertible preferred stock, shareholding, equity securities